newsfilter
← Latest News
GlobeNewswire·

Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Phase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits Established relationship with industry-leading CDMO providing designated manufacturing capacity for bel-sar